奥曲肽联合来曲唑治疗复发转移性乳腺癌的临床观察

Clinical observation of effects of octreotide combined with letrozole on recurrent metastasis breast cancer patients

目的探讨奥曲肽联合来曲唑对复发转移性乳腺癌患者的疗效。方法将61例生长抑素受体（somatostain receptor，SSTR）、ER和（或）PR阳性表达的复发转移乳腺癌患者分为3组：A组为未治疗组9例；B组为来曲唑治疗组21例；C组为奥曲肽联合来曲唑治疗组31例。比较3组患者6、12、18、24个月生存率和生活质量。结果A组6、12、18、24个月生存率分别为11．1％（1／9）、0％（0／9）、0％（0／9）、0％（0／9）：B组分别为76．2％（16／21）、28．6％（6／21）、9．5％（2／21）、4．8％（1／21）；C组分别为93．5％（29／31）、64．5％（20／31）、41．9％（13／31）、12．9％（4，31）。3组间6、12、18个月生存率差异有统计学意义（P〈0．05），其中C组优于B组和A组。结论奥曲肽可能是治疗SSTR阳性的复发转移乳腺癌的新的靶向药物：奥曲肽和来曲唑联合应用能提高复发转移性乳腺癌的生存率。该方法依从性好，易被患者接受。

Objective To study the curative effects of octreotide combined with letrozole on recurrent metastasis breast cancer patients. Methods The 61 recurrent metastasis breast cancer patients whose expression of somatostatin receptor （SSTR）, estrogen receptor （ER） and/or progesterone receptor（PR） were positive were di- vided into 3 groups： 9 cases in group A （non-treatment group）, 21 cases in group B （letrozole therapy group）, and 21 cases in group C （octreotide combined with letrozole therapy group）. The 6, 12, 18, and 24 months survival rate and life quality were compared between the 3 groups. Results The 6, 12, 18, and 24 months survival rate was 11.1%（1/9）, 0%（0/9）, 0%（0/9）, and 0%（0/9）respectively in group A, while it was 76.2 %（16/21）, 28.6 %（6/21）, 9.5 %（2/21）, and 4.8 % （1/21） in group B, and 93.5 %（29/31）, 64.5 %（20/31）, 41.9 %（13/31）, and 12.9 %（4/31）in group C. The difference of 6, 12, and 18 months survival rate between the 3 groups were statisti- cally diffenent （P〈0.05）. The life quality of group C was better than that of group A and group B. Conclusions Octreotide may be a new targeted drug to treat recurrent metastasis breast cancer with positive SSTR. Octreotide combined letrozole can improve the survival rate of breast cancer, and it is easy to be accepted by patients, with good compliance.